KLRK1 and neoplasm: NK cells can be altered by tumor-derived EVs containing immune checkpoint molecules PD-1, PD-L1 and CTLA-4, which impair their cytotoxic activity by downregulating the expression of Natural Killer Group 2 Member D Protein (NKG2D) on the surface of NK cells [99,103].